Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Am J Gastroenterol ; 93(3): 463-4, 1998 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-9517660

RESUMEN

Cutaneous necrosis may occur as a complication of treatment with interferon. Here we report the first case of cutaneous necrosis developing in a patient receiving interferon alpha-2b for the treatment of chronic hepatitis C viral infection. The patient developed two necrotic lesions while receiving high doses of interferon. We suggest that discontinuation of treatment may be necessary to permit healing of such lesions. Although the exact mechanism involved in cutaneous necrosis remains unknown, our observations support earlier findings suggesting that intraarterial injection may be a factor.


Asunto(s)
Interferón-alfa/efectos adversos , Piel/patología , Biopsia , Hepatitis C/tratamiento farmacológico , Hepatitis Crónica/tratamiento farmacológico , Humanos , Interferón alfa-2 , Interferón-alfa/uso terapéutico , Masculino , Persona de Mediana Edad , Necrosis , Proteínas Recombinantes
2.
Arch Intern Med ; 155(21): 2336-40, 1995 Nov 27.
Artículo en Inglés | MEDLINE | ID: mdl-7487259

RESUMEN

BACKGROUND: Three randomized controlled trials of the effectiveness of pneumococcal vaccine in elderly and chronically ill adults in the United States have failed to show significant protective efficacy during 44,213 person-years of follow-up. Case-control studies have greater statistical power to detect significant prevention of rare diseases such as pneumococcal bacteremia, but they also have a greater susceptibility to bias, necessitating consistent results from multiple studies. Three case-control studies at two different universities have shown prevention of systemic infection, but another study found no benefit. METHODS: Patients with pneumococcal bacteremia who were at least 2 years old and had chronic illness indicating the need for pneumococcal vaccine, or who were at least 65 years old were compared with matched control subjects for frequency of prior vaccination. Matching variables included date of admission, age, sex, race, type and duration of chronic illness serving as the major vaccine indication, number of vaccine indications and number of medical hospitalizations since licensure of the pneumococcal vaccine in 1978, and type of primary medical care. RESULTS: Pneumococcal vaccination was documented in the records of six (7%) of 85 cases and 26 (17%) of 152 control subjects, suggesting 81% efficacy in conditional logistical regression analysis (95% confidence interval, 34% to 94%, P = .008). CONCLUSIONS: Four case-control studies at three universities have now demonstrated significant protective efficacy of pneumococcal vaccine for preventing pneumococcal bacteremia. The development of antibiotic-resistant Streptococcus pneumoniae indicates an urgent need for an increased rate of vaccination among high-risk patients and for the development of more immunogenic conjugate vaccines that may enhance efficacy among elderly and immunocompromised patients as well as infants.


Asunto(s)
Bacteriemia/prevención & control , Vacunas Bacterianas/inmunología , Infecciones Neumocócicas/prevención & control , Streptococcus pneumoniae , Adolescente , Adulto , Anciano , Bacteriemia/microbiología , Sesgo , Estudios de Casos y Controles , Niño , Preescolar , Intervalos de Confianza , Farmacorresistencia Microbiana , Femenino , Humanos , Modelos Logísticos , Masculino , Análisis por Apareamiento , Persona de Mediana Edad , Infecciones Neumocócicas/microbiología , Vacunas Neumococicas , Factores de Riesgo , Streptococcus pneumoniae/inmunología
3.
N Engl J Med ; 327(15): 1062-8, 1992 Oct 08.
Artículo en Inglés | MEDLINE | ID: mdl-1522842

RESUMEN

BACKGROUND: The incidence of infection increases with the prolonged use of central vascular catheters, but it is unclear whether changing catheters every three days, as some recommend, will reduce the rate of infection, It is also unclear whether it is safer to change a catheter over a guide wire or insert it at a new site. METHODS: We conducted a controlled trial in adult patients in intensive care units who required central venous or pulmonary-artery catheters for more than three days. Patients were assigned randomly to undergo one of four methods of catheter exchange: replacement every three days either by insertion at a new site (group 1) or by exchange over a guide wire (group 2), or replacement when clinically indicated either by insertion at a new site (group 3) or by exchange over a guide wire (group 4). RESULTS: Of the 160 patients, 5 percent had catheter-related bloodstream infections, 16 percent had catheters that became colonized, and 9 percent had major mechanical complications. The incidence rates (per 1000 days of catheter use) of bloodstream infection were 3 in group 1, 6 in group 2, 2 in group 3, and 3 in group 4; the incidence rates of mechanical complications were 14, 4, 8, and 3, respectively. Patients randomly assigned to guide-wire-assisted exchange were more likely to have bloodstream infection after the first three days of catheterization (6 percent vs. 0, P = 0.06). Insertions at new sites were associated with more mechanical complications (5 percent vs. 1 percent, P = 0.005). CONCLUSIONS: Routine replacement of central vascular catheters every three days does not prevent infection. Exchanging catheters with the use of a guide wire increases the risk of bloodstream infection, but replacement involving insertion of catheters at new sites increases the risk of mechanical complications.


Asunto(s)
Cateterismo Venoso Central/métodos , Cateterismo/métodos , Arteria Pulmonar , Antisepsia , Bacteriemia/prevención & control , Bacterias/aislamiento & purificación , Cateterismo/efectos adversos , Cateterismo Venoso Central/efectos adversos , Catéteres de Permanencia/efectos adversos , Contaminación de Equipos , Falla de Equipo , Humanos , Factores de Tiempo
4.
Infect Control Hosp Epidemiol ; 13(9): 515-25, 1992 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-1430999

RESUMEN

OBJECTIVE: To compare the frequency of the pathogens of nosocomial pneumonia in a community-based teaching hospital to the frequencies previously published, and to evaluate recommendations for the therapy of nosocomial pneumonia in this setting. DESIGN: Retrospective review of prospectively acquired data accrued during 9 randomized single-blinded and 4 single-agent investigational antibiotic studies for the therapy of pneumonia in hospitalized patients between 1981 and 1989. SETTING: The study was performed at a university affiliated, community-based teaching Department of Veterans Affairs Medical Center. PATIENTS: Patients were hospitalized on the acute medical/surgical and intermediate medicine wards. Informed consent was obtained prior to enrolling patients into the respective antimicrobial studies. Pneumonia was documented radiographically and clinically for each patient. RESULTS: Two hundred thirty-one episodes of nosocomial pneumonia were treated. Overall, 51% of pneumonias were caused by Streptococcus pneumoniae or Hemophilus influenzae with or without other organisms that were not gram-negative bacilli. Gram-negative bacilli, with or without other organisms, accounted for only 26% of all nosocomial pneumonias. Overall, monotherapy with a cephalosporin (usually a broad-spectrum agent) was equally efficacious compared with combination therapy (87% versus 81%, respectively). Cure rates for nosocomial pneumonias from gram-negative bacilli treated with these 2 therapies also were similar (70% versus 60%, respectively). CONCLUSIONS: In nontertiary care settings, gram-negative bacilli may cause fewer episodes of nosocomial pneumonia (26% in this study) than noted by previously published reports, which indicated that these organisms account for 50% of nosocomial pneumonias. Further, S pneumoniae and H influenzae may account etiologically for many of these nosocomial pneumonias. Monotherapy with an extended-spectrum cephalosporin may be more appropriate than combined treatment with a beta-lactam and an aminoglycoside in a nontertiary care setting, thereby reducing potential toxicity in an older, hospitalized patient population.


Asunto(s)
Infección Hospitalaria/tratamiento farmacológico , Infección Hospitalaria/microbiología , Neumonía/tratamiento farmacológico , Neumonía/microbiología , Adulto , Anciano , Anciano de 80 o más Años , Cefalosporinas/uso terapéutico , Femenino , Infecciones por Haemophilus/tratamiento farmacológico , Infecciones por Haemophilus/microbiología , Haemophilus influenzae , Hospitales con 100 a 299 Camas , Hospitales Comunitarios , Hospitales de Enseñanza , Hospitales de Veteranos , Humanos , Masculino , Persona de Mediana Edad , Infecciones Neumocócicas/tratamiento farmacológico , Infecciones Neumocócicas/microbiología , Estudios Retrospectivos , Método Simple Ciego , Virginia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA